|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
European Patient Summary
|
|
|
|||||||||||||||||||
Problem list
| Condition | Onset Date / Period | Status |
|---|---|---|
| Anemia | 02-Jun-2009 | active |
| Acute bronchitis | 13-Jan-2025 - 25-Jan-2025 | inactive |
| Laceration of foot | 22-Mar-2021 - 11-Apr-2021 | inactive |
| Laceration - injury | 22-Mar-2021 - 11-Apr-2021 | inactive |
Medication list
| Medication | Since | Form | Dosage | Reason |
|---|---|---|---|---|
| Fexofenadine hydrochloride 60 mg oral tablet | 1999-07-27 | - | 1 tablet (60 mg) twice daily | - |
| Epinephrine 1 mg/mL solution for injection | 1999-07-27 | - | 0.3 mg (1 mg/mL) injected intramuscularly as needed for severe allergic reaction | - |
| Hydrocortisone 10 mg/g and urea 100 mg/g cutaneous cream | 1999-07-07 | - | Apply a thin layer (hydrocortisone 10 mg/g and urea 100 mg/g) to the affected area 2 times daily | Contact dermatitis |
Immunizations list
| Vaccine | Date |
|---|---|
| Influenza virus antigen only vaccine product | 21-Jan-2025 |
| Clostridium tetani toxoid antigen adsorbed only vaccine product | 21-Mar-2023 |
| Live attenuated Human alphaherpesvirus 3 only vaccine product | 21-Mar-2023 |
| SARS-CoV-2 mRNA vaccine | 07-Sep-2021 |
Procedure History list
| Procedure | Date | Reason |
|---|---|---|
| Suture open wound | 22-Mar-2021 | Laceration of foot (disorder) |
Allergies and Intolerances
| Allergy/Intolerance | Onset Date | Status | Type | Reaction |
|---|---|---|---|---|
| Aspirin | 1999-07-27 | active | medication | |
| Allergy to drug | 1999-07-27 | active | environment |
Care Plan
| Active Planned Care / Goals | Start Date | Reason |
|---|---|---|
| Diabetes self management plan | 30-May-2006 | Prediabetes (finding) |
|
||
| Self-care interventions | 27-Jul-1999 | - |
Vital Signs
| Vital Signs | 2025-04-01 | 2025-01-21 |
|---|---|---|
| Body Height | 171.6 cm | 171.6 cm |
| Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 {score} | 1 {score} |
| Body Weight | 106.7 kg | 106.7 kg |
| Body mass index (BMI) [Ratio] | 36.2 kg/m2 | 36.2 kg/m2 |
| Heart rate | 65 /min | 90 /min |
| Respiratory rate | 14 /min | 14 /min |
| Blood pressure panel with all children optional | 81 mm[Hg] | 85 mm[Hg] |
Relevant diagnostic tests/laboratory data
| Recent Lab Observations | 01-APR-2025 | Reference Range | Unit |
|---|---|---|---|
| Hemoglobin A1c/Hemoglobin.total in Blood | 6.2 H | 4.8 - 5.9 | % |
| Glucose [Mass/volume] in Blood | 92.7 | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 9.0 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Blood | 1.3 H | 0.6 - 1.2 | mg/dL |
| Calcium [Mass/volume] in Blood | 9.7 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 141.1 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 4.6 | 3.5 - 5.0 | mmol/L |
| Chloride [Moles/volume] in Blood | 107.6 H | 98 - 107 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 24.5 | 22 - 29 | mmol/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 165.4 | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 124.0 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 107.6 H | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 33.0 L | 40 - 60 | mg/dL |
Device Use
| Device | Date (since) |
|---|---|
| Blood glucose meter (physical object) | 30-May-2006 |